All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
On 26 March 2019, the US Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation to ivosidenib, a first-in-class, oral, selective inhibitor of mutations in isocitrate dehydrogenase-1 (IDH1), in combination with azacitidine, for the treatment of patients with newly diagnosed IDH1-mutant acute myeloid leukemia (AML). This comes after ivosidenib received FDA approval in July 2018 for the treatment of patients with IDH1-mutant relapsed/refractory AML.
The Breakthrough Therapy Designation for ivosidenib and azacitidine was based on the results from a phase I/II study, which were presented at the Acute Leukemias XVII Biology and Treatment Strategies biennial symposium. In the ivosidenib and azacitidine arm, the overall response rate was 78%, with a complete response rate of 57%. Moreover, the median duration of response in the ivosidenib and azacitidine arm was not reached (95% CI, 7.7–not reached).
According to the drug manufacturers, the combination of ivosidenib and azacitidine for patients with newly diagnosed AML “has the potential to be a compelling treatment option”, because at present in the front-line setting there are “no approved options specifically for patients with an IDH1 mutation.”
References